In Vitro Activity of Colistin (Polymyxin E) against 3,480 Isolates of Gram-Negative Bacilli Obtained from Patients in Canadian Hospitals in the CANWARD Study, 2007-2008 | Zendy

Andrew Walkty | Zendy; Melanie DeCorby | Zendy; Kimberly A. Nichol | Zendy; James A. Karlowsky | Zendy; D. J. Hoban | Zendy; George G. Zhanel | Zendy

Open Access

In Vitro Activity of Colistin (Polymyxin E) against 3,480 Isolates of Gram-Negative Bacilli Obtained from Patients in Canadian Hospitals in the CANWARD Study, 2007-2008

Author(s) -

Andrew Walkty,

Melanie DeCorby,

Kimberly A. Nichol,

James A. Karlowsky,

D. J. Hoban,

George G. Zhanel

Publication year - 2009

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00786-09

Subject(s) - colistin , polymyxin , bacilli , microbiology and biotechnology , gram , polymyxin b , gram negative bacteria , in vitro , medicine , gram negative bacterial infections , biology , antibiotics , bacteria , escherichia coli , biochemistry , genetics , gene

The in vitro activity of colistin was evaluated versus 3,480 isolates of gram-negative bacilli using CLSI broth microdilution methods. The MIC(90) of colistin was < or = 2 microg/ml against a variety of clinically important gram-negative bacilli, including Escherichia coli, Klebsiella spp., Enterobacter spp., Acinetobacter baumannii, and Pseudomonas aeruginosa. All multidrug-resistant (n = 76) P. aeruginosa isolates were susceptible to colistin (MIC, < or = 2 microg/ml). These data support a role for colistin in the treatment of infections caused by multidrug-resistant P. aeruginosa.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research